Prof Dr. Nives Pećina-Šlaus – Cancer Genetics – Best Researcher Award

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILE 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cells—Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue “Advances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

 

 

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

 

Prof. Vincenzo Quagliariello – Cardio-oncology – Best Researcher Award

Prof. Vincenzo Quagliariello - Cardio-oncology - Best Researcher Award

Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale - Italy

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Dr. Vincenzo Quagliariello embarked on his academic journey by specializing in Clinical Biochemistry and Clinical Pathology at the University of Campania Luigi Vanvitelli. This laid the groundwork for his future endeavors in the medical field.

PROFESSIONAL ENDEAVORS

His professional journey saw him contribute significantly to the field of medical research. He held a fixed-term contract as a "Health Researcher DS6" at the prestigious Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Division of Cardiology, where he made notable contributions to the study of cardiology.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIO-ONCOLOGY

Dr. Quagliariello's research focus spans various areas, including biochemistry, clinical pathology, and cardiology. Notably, he has participated as a speaker in numerous national and international congresses since 2011, showcasing his expertise and sharing valuable insights with the scientific community.

IMPACT AND INFLUENCE

His contributions to the field of medical research are underscored by his involvement in the development of innovative medical devices and pharmaceutical formulations aimed at enhancing the efficacy of cancer treatment. Dr. Quagliariello's work has the potential to positively impact patient care and outcomes.

ACADEMIC CITATIONS

Dr. Quagliariello's work has likely garnered attention within the academic community, potentially leading to citations in scholarly literature. His involvement in pioneering research projects and participation in congresses further solidify his standing in the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Quagliariello's legacy lies in his dedication to advancing medical science, particularly in the fields of Cardio-oncology. His innovative patents and contributions to scientific literature lay the foundation for future breakthroughs in cancer treatment and cardiovascular medicine. As he continues his academic and professional journey, he is poised to make even greater contributions to the field, leaving a lasting impact on healthcare and patient outcomes.

NOTABLE PUBLICATIONS

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients. 2024

Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology? 2022 (12)

The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. 2022 (24)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. 2021 (199)

Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives. 2021 (40)

 

 

 

 

 

 

 

 

 

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Dr. VICTOR NAVA – Pathology – Best Researcher Award

Dr. VICTOR NAVA - Pathology - Best Researcher Award

GEORGE WASHINGTON UNIVERSITY - United States

AUTHOR PROFILE

Google Scholar
Orcid
Scopus

EARLY ACADEMIC PURSUITS

Victor Eduardo Nava began his academic journey at the Central University of Venezuela, where he pursued his Medical Degree from 1983 to 1990. This foundational education provided him with the essential knowledge and skills in medicine.After obtaining his M.D., Victor Eduardo Nava furthered his academic pursuits at Tulane University's Graduate School. Here, he earned a Master of Science degree from the Department of Parasitology in 1993.Continuing his academic journey, Nava pursued a Ph.D. at Johns Hopkins University's School of Public Health. Under the guidance of his advisor, J. Marie Hardwick, Ph.D., he specialized in Molecular Microbiology and Immunology, completing his doctoral studies in 1998.

PROFESSIONAL ENDEAVORS

Victor Eduardo Nava undertook his PGY1 Residency in Anatomic Pathology/Clinical Pathology at Georgetown University Hospital under the mentorship of Norio Azumi, M.D., Ph.D., in 2001-2002.From 2002 to 2004, Nava continued his residency in Anatomic Pathology at the National Institutes of Health/National Cancer Institute's Laboratory of Pathology. His mentors during this period were Elaine Jaffe, M.D., and Maria Merino, M.D. Nava completed a fellowship in Hematopathology at Georgetown University Hospital from 2004 to 2006, mentored by Metin Ozdemirli, M.D., Ph.D.

CONTRIBUTIONS AND RESEARCH FOCUS ON PATHOLOGY

Throughout his career, Victor Eduardo Nava has made significant contributions to the field of Pathology, particularly in Hematopathology and Surgical Pathology. His research has focused on molecular microbiology, immunology, and the pathology of hematological disorders.

IMPACT AND INFLUENCE

Dr. Nava's work has had a profound impact on the understanding and diagnosis of hematological diseases. His research and clinical expertise have influenced medical practices and contributed to advancements in the field of pathology.

ACADEMIC CITES

Victor Eduardo Nava has been recognized for his scholarly contributions with numerous citations in academic journals and publications. His research papers and studies have been referenced by peers and professionals in the field, highlighting the significance and relevance of his work.

LEGACY AND FUTURE CONTRIBUTIONS

As the Blood Bank Director and Attending Hematopathologist/Surgical Pathologist at the Veterans Affairs Medical Center in Washington, DC, and Assistant Professor at George Washington University since 2007, Dr. Nava continues to make a lasting impact. His dedication to teaching, research, and patient care ensures that his legacy will endure, with future contributions expected to further advance the field of Pathology.

NOTABLE PUBLICATIONS

Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing. 2024

Myelodysplastic Neoplasms (MDS): A Narrative Review from the Era of Precision Medicine. 2024

Novel Therapeutics for Malaria. 2023

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V<sup>2</sup>) Therapy. 2022

Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. 2022